Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.
The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.
“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.
Click this link for the original source of this article.
Author: Helen Branswell
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.